Warren Whyte

Warren Whyte is the current VP of RWE Sciences at ConcertAI. Warren has also been the PHI and RWD Lead at Accenture since June 2015. In this role, they are responsible for directing a pharmaceutical company in leveraging RWE to gauge unmet needs related to heart failure and associated therapies, as well as creating an RLE strategy for their pipeline products. Warren has also led a global pharma company in identifying and building patient-based solutions that leverage diagnostic and analytical services to improve outcomes through better practice decisions, improved screening, and coordinated patient care throughout the prostate cancer care continuum.

Warren Whyte received a B.A. in Molecular and Cell Biology from Cornell University, graduating magna cum laude. Warren then went on to earn their Ph.D. in Biology from the Massachusetts Institute of Technology.

Warren Whyte reports to Nathalie Horowicz-Mehler, SVP & GM, RWE Sciences.